Microbial findings and the role of difficult-to-treat pathogens in patients with periprosthetic infection admitted to the intensive care unit

Christopher Ull,1 Emre Yilmaz,1 Hinnerk Baecker,1 Thomas Armin Schindhauer,1 Christian Waydhas,1,2 Uwe Hamsen1
1Department of General and Trauma Surgery, BG University Hospital Bergmannsheil, Bochum; 2Medical Faculty University Duisburg-Essen, Germany

Abstract

Little is known about patients with Periprosthetic Joint Infection (PJI) admitted to the Intensive Care Unit (ICU). The purpose of this study was threefold: i) To report the microbiological findings of ICU-patients with PJI. ii) To compare the clinical data between Difficult-To-Treat (DTT) and non-DTT PJI. iii) To identify risk factors for mortality. This is a retrospective study from a tertiary healthcare center in Germany from 2012-2016. A total of 124 patients with 169 pathogens were included. The most common bacteria were Staphylococcus aureus (26.6%), Staphylococcus epidermidis (12.4%), Enterococci ssp. and Escherichia coli (respectively 9.4%). DTT PJI was diagnosed in 28 patients (22.6%). The main pathogens of DTT PJI were Staphylococcus epidermidis (14.5%), Escherichia coli (12.7%), Staphylococcus aureus and Candida spp. (respectively 9.1%). Polymicrobial PJI, number of pathogens, ICU stay and mortality were significantly different between DTT PJI and non-DTT PJI (p<0.05). Multivariate logistic regression identified prolonged ICU stay and DTT PJI as risk factors for mortality. In conclusion, we suggest, that the term of DTT pathogens is useful for the intensivist to assess the clinical outcome in ICU-patients with PJI.

Materials and Methods

This retrospective, observational, single-center study was performed in a 13-bed surgical ICU of a tertiary healthcare center in Germany. It has been approved by the local ethics committee (no. of approval 18-6260-BR). Included were all patients with acute or chronic PJI of the hip, knee or both who need ICU treatment after hip or knee replacement surgery between January 1, 2012 and December 31, 2016. Patients with PJI were identified using the international classification of diseases, 10th revision (ICD-10) codes T84.5, T84.6, T84.7, T84.8 and T84.9. The decision for admission to ICU after surgery were made by the anesthesiologist based on their assessment or the leading intensivist. The ICU is accompanied by a stand-alone Intermediate Care Unit (IMC). The resources and therapeutic repertoire of the IMC include standard ICU monitoring, non-invasive ventilation, and continuous vasoressor-administration. The IMC is intensivist-led and provides 24-hour coverage by residents experienced in intensive care. The majority of surgical PJI-patients were admitted to the IMC and were not included in our study.

The demographic and clinical data of the included 124 patients were recently published.13 As published before, severity of illness were detected using the Simplified Acute Physiology Score II (SAPS II),14 the American Society of Anaesthesiologists Score (ASA)15 and the Charlson Comorbidity Index (CCI).16

PJI were defined according to the European Bone and Joint Infection Society17 and Musculoskeletal Infection Society18 (Table 1). Acute or chronic PJI were classified according to the definition as described by Li et al.19

For diagnosis of a PJI, joint aspiration and periprosthetic tissue samples such as...
sonication fluid of the retrieved implant were analyzed after an incubation time of 14 days. Two or more positive microbial culture pathogens were necessary to diagnose PJI. The intra-operative detected pathogens of the patients PJI were classified into DTT or non-DTT pathogens. DTT pathogens included rifampin-resistant staphylococci, vancomycin-resistant enterococci, ciprofloxacin-resistant Gram negative bacteria, and Candida spp.\(^3\)\(^4\) The outcome measurements were: i) to report the error of 0.05. Further statistical analysis were with an average effect size of 0.3 and an alpha error of 0.05 and an average effect size of 0.3. Power analysis was done with G*Power\(^\text{®}\) Version 3.1 (Heinrich-Heine University of Dusseldorf, Germany) and showed a sample size of \(n=28\) for a power of 0.95 with an alpha error of 0.05 and an average effect size of 0.3. The post hoc analysis showed for our study sample size with 124 patients a power of 1.0 with an average effect size of 0.3 and an alpha error of 0.05. Further statistical analysis were performed using Microsoft\(^\text{®}\) Office Excel\(^\text{®}\) for Mac 2019 (Microsoft Corporation, Redmond, Washington, USA) and IBM\(^\text{®}\) SPSS\(^\text{®}\) Statistics Version 26 2019 (IBM Corporation, Armonk, New York, USA). The data are presented as mean and standard deviation or as absolute numbers and percentage. Categorial data were tested using the Chi-square test or Fisher’s exact test. Continuous data were compared using Student’s t test or Mann-Whitney U test. All significant univariate trends were entered into a multivariate (binary logistic) analysis to identify risk factors for mortality. Significance was set at \(p<0.05\).

**Statistical analysis**

Power analysis was done with G*Power\(^\text{®}\) Version 3.1 (Heinrich-Heine University of Dusseldorf, Germany) and showed a sample size of \(n=28\) for a power of 0.95 with an alpha error of 0.05 and an average effect size of 0.3. The post hoc analysis showed for our study sample size with 124 patients a power of 1.0 with an average effect size of 0.3 and an alpha error of 0.05. Further statistical analysis were performed using Microsoft\(^\text{®}\) Office Excel\(^\text{®}\) for Mac 2019 (Microsoft Corporation, Redmond, Washington, USA) and IBM\(^\text{®}\) SPSS\(^\text{®}\) Statistics Version 26 2019 (IBM Corporation, Armonk, New York, USA). The data are presented as mean and standard deviation or as absolute numbers and percentage. Categorial data were tested using the Chi-square test or Fisher’s exact test. Continuous data were compared using Student’s t test or Mann-Whitney U test. All significant univariate trends were entered into a multivariate (binary logistic) analysis to identify risk factors for mortality. Significance was set at \(p<0.05\).

**Results**

A total of 169 microbial pathogens were detected in 124 ICU-patients with isolated Gram positive bacteria in 73.3%, Gram negative bacteria in 23.6% and Candida spp. in 2.9% of all patients. The most common bacterium was *Staphylococcus aureus* (26.6%), followed by *Staphylococcus epidermidis* (12.4%), *Enterococci* spp. and *Escherichia coli* (respectively 9.4%). A monomicrobial PJI was found in 93 patients (74.9%) and a polymicrobial PJI in 30 patients (24.2%). A negative culture was only seen in one patient with PJI (0.8%). These data are listed in detail in Tables 2 and 3. Gram positive and Gram negative microbial pathogens were found in 15 cases (15.3%) of polymicrobial PJI, multiple Gram positive in 6 cases (4.8%) and Gram positive and Candida in 5 cases (4%). Eighteen patients showed a polymicrobial PJI with 2 microbial pathogens (60%), 8 patients with 3 microbial pathogens (16.6%), 2 patients with 4 microbial pathogens (6.6%) and one patient had a PJI with 5 microbial pathogens (3.3%).

DTT PJI was diagnosed in 28 patients (22.6%) with 10 monomicrobial PJI (35.6%) and 18 polymicrobial PJI (64.3%). The main pathogens of DTT PJI were *Staphylococcus epidermidis* (14.5%), *Escherica coli* (12.7%), *Staphylococcus aureus* and *Candida* spp. (respectively 9.4%). As shown in Table 3, a total of 41 different microbial pathogens were detected in polymicrobial DTT PJI with 21 DTT pathogens and 20 associated non-DTT Co-pathogens. Fourteen out of 16 patients (87.5%) with

### Table 1. Criteria for PJI

| European Bone Joint Infection Society criteria\(^5\) | Musculoskeletal Infection Society criteria\(^6\) |
|---------------------------------------------------|-----------------------------------------------|
| A PJI is diagnosed if at least one of the following criteria is fulfilled: | This is an Adaptation of the Musculoskeletal Infection Society Definition of PJI. |
| 1) Clinical: sinus tract (fistula) or purulence around prosthesis | PJI Is Present When One of the Major Criteria Exists or Three Out of Five Minor Criteria Exist |
| 2) Cell count in joint aspiration: >2000 µ/l leucocytes or >70% polymorphonuclear granulocytes (PMN) | Major Criteria: |
| 3) Histology: inflammation in periprosthetic tissue (type 2 or 3 after Krenn and Morawietz) | Two positive periprosthetic cultures with phenotypically identical organisms, OR |
| 4) Microbial growth in synovial fluid or ≥2 tissue samples | A sinus tract communicating with the joint, OR |
| (in cases of high virulent microbes like *Staphylococcus aureus* | Minor Criteria |
| one sample is considered sufficient) or sonication fluid ≥50 CFU/ml | 1) Elevated serum C-reactive protein (CRP) AND erythrocyte sedimentation rate (ESR) |
| 5) A single positive culture | 2) Elevated synovial fluid white blood cell (WBC) count OR ++change on leukocyte esterase test stri |
| 2 tissue samples | 3) Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%) |
| Minor Criteria | 4) Positive histological analysis of periprosthetic tissue (KRENN) |
| 1) Clinical: sinus tract (fistula) or purulence | 5) A single positive culture |
| around prosthesis | |

**Abbreviations:** PJI periprosthetic joint infection.

### Table 2. Microbial findings in 124 patients with PJI.

| All PJI, n=124 (%) | DTT PJI, n=28 (%) | Non-DTT PJI, n=95 (%) |
|--------------------|------------------|---------------------|
| Monomicrobial PJI  |                  |                     |
| Gram-positive bacteria | 72 (58)          | 6 (21.4)            | 30 (31.5) |
| *Staphylococcus* spp. | 53 (42.7)        | 6 (21.4)            | 30 (31.5) |
| *Staphylococcus aureus* | 31 (25)         | 1 (3.5)             | 30 (31.5) |
| *Staphylococcus* *epidermidis* | 16 (12.9)     | 5 (17.8)            | 11 (11.5) |
| Coagulase-negative *staphylococci* | 6 (4.8)          | -                   | 4 (4.2) |
| *Streptococcus* spp. | 9 (7.2)          | -                   | 4 (4.2) |
| *Enterococcus* spp. | 4 (3.2)          | -                   | 4 (4.2) |
| Other\(^1\) | 6 (4.8)          | -                   | 6 (6.3) |
| Gram-negative bacteria | 21 (16.9)        | 4 (14.3)            | 17 (17.9) |
| *Escherichia coli* | 10 (8)           | 4 (14.3)            | 6 (6.3) |
| *Enterobacteriaceae* spp.\(^2\) | 9 (7.2)         | -                   | 9 (9.4) |
| *Pseudomonas* *aeruginosa* | 2 (1.6)         | -                   | 2 (2.1) |
| Polymicrobial PJI | 30 (24.2)        | 18 (64.3)           | 12 (12.6) |
| Negative culture | 1 (0.8)          | -                   | - |

Data presented as absolute Number (Percentage). Abbreviations: PJI periprosthetic joint infection, DTT difficult to treat; \(^1\)including *Clostridium* spp. (n=3), *Micrococcus* spp. (n=2), *Pediococcus* spp. \(^2\)including *Enterobacter* spp. (n=4), *Klebsiella* spp. (n=3), *Citrobacter* spp., *Serratia marcescens*.
multidrug resistant pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA), multiresistant Gram negative bacteria that are not susceptible to 3 specific groups of antibiotics (3MRGN) and Vancomycin-Resistant *Enterococci* (VRE) as the reason for PJI showed DTT pathogens.

The demographic and clinical data of the included 124 patients were recently published.¹³ In univariate analysis, polymicrobial PJI [18 (64.3%) vs. 12 (12.5%); *p*=0.001], number of pathogens [2±0.9 vs. 1.2±0.6; *p*=0.001], ICU stay [17.8±18 vs. 10.6±13.1; *p*=0.05] and mortality [11 (39.2%) vs. 15 (15.6%); *p=0.007] were found to be significantly different between DTT PJI and non-DTT PJI (Table 4). Multivariate logistic regression identified prolonged ICU stay

**Table 3. Microbial findings in 30 patients with polymicrobial PJI.**

| All, n=76 (%) | DTT, n=45 (%) | Non-DTT, n=31 (%) |
|--------------|--------------|------------------|
| **Gram-positive bacteria** | | |
| *Staphylococcus aureus* | 4 (25) | 23 (75) |
| *Staphylococcus epidermidis* | 3 (15) | 3 (15) |
| *Coagulase-negative staphylococci* | 1 (5) | 5 (20) |
| *Enterococcus spp.* | 7 (35) | 5 (25) |
| **Other** | | |
| | 6 (25) | 3 (12) |
| **Gram-negative bacteria** | | |
| *Escherichia coli* | 12 (60) | 3 (12) |
| *Enterobacteriaceae spp.* | 3 (15) | 2 (8) |
| *Pseudomonas aeruginosa* | 1 (5) | 1 (4) |
| *Proteus mirabilis* | 7 (35) | 1 (4) |
| **Other** | | |
| | 2 (10) | 1 (4) |
| **Candida spp.** | 5 (25) | 7 (35) |

Data presented as absolute number (percentage). Abbreviations: DTT difficult-to-treat. ¹ Including *Bacillus spp.*, *Coagulobacterium spp.*, *Lecan mobacter*, *Propioni bacterium* spp. ² Including *Klebsiella* (n=3), *Acinetobacter spp.*, *Citrobacter* spp., *Enterobacter* spp., *Serratia* spp.

**Table 4. Clinical findings in 124 patients with PJI.**

|                | DTT PJI, n=28 (%) | Non-DTT PJI, n=96 (%) | *P* value |
|----------------|-------------------|-----------------------|-----------|
| Male gender    | 11 (39.2)         | 41 (42.7)             | 0.71      |
| Age            | 77.7±10.9         | 74.4±12.4             | 0.2       |
| BMI            | 27.1±10.9         | 29±7.5                | 0.31      |
| Location of the PJI | | | |
| Hip            | 20 (71.4)         | 65 (67.7)             | 0.76      |
| Knee           | 6 (18.1)          | 27 (28.1)             | 0.52      |
| Hip and knee   | 2 (7.1)           | 4 (4.1)               | 0.52      |
| No. of patients with previous septic revisions since TA | 20 (71.4) | 61 (63.5) | 0.47 |
| No. of previous septic revision since TA | 3.3±3.8 | 2.9±3.3 | 0.55 |
| No. of surgeries during hospitalization | 2.8±1.6 | 2.1±1.8 | 0.07 |
| Reasons for ICU admission | | | |
| Unplanned surgical | 9 (32.1) | 34 (35.4) | 0.59 |
| Medical        | 3 (10.7)          | 16 (16.6)             | 0.59      |
| Scheduled surgical | 16 (57.1) | 46 (47.9) | 0.59 |
| CCI            | 4.6±2.1           | 3.1±2.5               | 0.09      |
| ASA Score      | 3.1±0.6           | 3.1±0.5               | 0.4       |
| SAPS II Score  | 25.3±18.2         | 23.7±15.7             | 0.62      |
| Invasive ventilation | 12 (42.8) | 25 (26) | 0.09 |
| Hours of ventilation | 109.1±124.1 | 123.9±254.7 | 0.85 |
| RRT            | 4 (14.2)          | 11 (11.4)             | 0.74      |
| Acute PJI      | 4 (14.2)          | 15 (15.6)             | 0.55      |
| Polymicrobial PJI | 18 (64.2) | 12 (12.5) | ≤0.001 |
| No. of pathogens | 2±0.9 | 1.2±0.6 | ≤0.001 |
| LOS ICU        | 17.8±18           | 10.6±13.1             | 0.05      |
| LOS hospital   | 54±28.8           | 46±39                 | 0.31      |
| Mortality      | 11 (39.2)         | 15 (15.6)             | 0.007     |

Data presented as mean±standard deviation or as absolute numbers (percentage). Significant results are in italics. Abbreviations: BMI body mass index, No. number, TA total arthroplasty, CCI Charlson Comorbidity Index, ASA Score American Association of Anesthesiologist Score, SAPS II Score Simplified Acute Physiology Score II, RRT renal replacement therapy, LOS length of stay, ICU Intensive Care Unit, DTT difficult-to-treat.

[Orthopedic Reviews 2020; 12:8867]
(OR, 1.05; 95% CI, 1.01-1.09; p=0.01) and DTT PJI (odds ratio [OR], 3.35; 95% confidence interval [CI], 1.11-12.1; p=0.049) as risk factors for mortality (Table 5).

After discharge from the ICU, 98 out of 124 patients (79%) survived the in-hospital stay and were discharged to rehabilitation (21.4%), nursing home (25.5%) or home (53.1%).

Discussion

We analyzed a large cohort of 124 ICU-patients with the treatment of PJI at a tertiary healthcare center. To our best knowledge, this is the first study showing the microbial findings and clinical data of patients with DTT PJI admitted to the ICU.

The first finding of our study is that the distribution of involved pathogens in ICU-patients with PJI was in accordance with that reported in the literature. The most common microbial pathogens were Staphylococcus aureus and Staphylococcus epidermidis, as noted previously in studies with large cohorts of patients with PJI.20-22 The proportions of Gram negative bacteria and Candida spp. were also similar to our findings.11,21

However, only one negative culture was found in our series, which seems to be very low compared to other studies with a rate up to 21%.23 The main reason for that may be the high number of septic revisions in our cohort with repeated samples of periprosthetic tissue, synovial fluid and the use of sonication to improve the likelihood of detecting microbial pathogens, as recommended before.23

Polymicrobial PJI were detected in 24.2% of all critically ill patients in our study. Although there were several factors like an age older than 65 years, higher ASA scores andCCI as well as multiple revisions surgeries that are associated with polymicrobial PJI in our findings, we found no higher rates of polymicrobial PJI than previously published.24-26

Currently, only one study has investigated the microbial findings of patients with PJI in an ICU.11 Maaloum et al. described the clinical spectrum and outcome of 41 critically ill patients suffering from PJI in a retrospective, observational study in 2013. Their microbial spectrum was nearly similar to our findings, with a proportion of 76% Gram positive and 20% Gram negative bacteria and polymicrobial PJI in 24% of all patients. The only difference of Maaloum et al. to our microbial spectrum was the detection of anaerobe bacteria and no detection of Candida spp.

Our second finding is that patients with DTT PJI showed more polymicrobial PJI with a higher number of microbial pathogens and a poorer outcome compared to non-DTT PJI. The role of DTT pathogens in patients with PJI is controversially discussed in the current literature. Some authors hypothesized that the treatment of DTT PJI is more challenging than non-DTT PJI with worse outcome.4,27 DTT pathogens were first described as rifampin-resistant staphylococci, ciprofloxacin-resistant Gram negative bacteria, enterococci and fungi (mainly Candida spp.).4,28

Renz et al. showed a treatment success of 84% in enterococcal PJI, suggesting that enterococci were not DTT. According to the current recommendation of the PRO-IMPLANT foundation only vancomycin-resistant enterococci were defined as DTT next to rifampin-resistant staphylococci, ciprofloxacin-resistant Gram negative bacteria and Candida spp.3 This revised definition of DTT pathogens was used in our study, too.

We found DTT pathogens in 22.6% of all ICU-patients with PJI, especially in polymicrobial PJI (64.2%). Rifampin-resistant Staphylococcus spp. were responsible as the microbial agents for DTT PJI in 12 patients (42.8%), Ciprofloxacin-resistant Gram negative bacteria for DTT in 11 patients (39.3%) and Candida spp. for DTT PJI in 5 patients (17.8%).

Akgün et al. found a rate of 18.4% DTT pathogens in 163 patients with PJI of the hip or knee.9 Main DTT pathogens were enterococci, followed by rifampin-resistant Staphylococcus epidermidis and fungi. The rate of polymicrobial PJI in patients with DTT pathogens was 53.3%. No ciprofloxacin-resistant Gram negative bacteria were detected. These findings were also shown in a study by Faschingbauer et al.10 DTT pathogens were present in 6.3% of all cases, but only 2.1% of PJI were polymicrobial.

These studies showed a significantly longer LOS in the hospital, longer prosthetic-free intervals, longer duration of antibiotic treatment and higher numbers of septic revisions compared to patients with non-DTT PJI.9,10 Interestingly, the treatment success at Follow Up (FU) of 24 months was not different between DTT and non-DTT PJI. We found no differences in LOS in hospital or in the number of revision surgeries in our ICU-patients with DTT or non-DTT PJI.

However, both studies with DTT PJI used the first described classification of DTT pathogens2-4 and reported no results of ICU-patients, which limits the ability to compare our results significantly.9,10 Moreover, FU of less than 24 months after hip or knee replacement was an exclusion criteria in these studies and the mortality rate was also not listed.

Despite these limitations, we confirm the findings of Akgün et al. that DTT pathogens are more common in polymicrobial PJI. In addition, we suggest that ciprofloxacin-resistant Gram negative bacteria might play an important role in the setting of DTT PJI in critically ill patients and might be more often the cause of DTT PJI, than previously has been published.3,9,10

The last finding of our study is that prolonged ICU stay and DTT PJI are risk factors for mortality in patients with PJI. As previously published, overall mortality of our cohort was 21%.13 This rate was similar to the findings of Maaloum et al.11 Acute infection of less than 4 weeks duration, renal replacement therapy (RRT), a high SAPS II Score and a high ASA Score were associated with a high mortality rate in their study. No differences could be found regarding age or type of bacteria. However, the term of DTT pathogens was not used in their study to compare this subgroup with our data.

We found a mortality rate of nearly 40% in patients with DTT PJI compared to 16%

Table 5. Multivariate logistic regression of risk factors for mortality.

| Risk Factor                | OR   | 95% CI       | p value |
|----------------------------|------|--------------|---------|
| LOS ICU                    | 1.05 | 1.01-1.09    | 0.01    |
| DTT PJI                    | 3.35 | 1.00-11.21   | 0.049   |
| Polymicrobial PJI          | 5.4  | 0.44-66.34   | 0.18    |
| Number of pathogens        | 0.25 | 0.04-1.36    | 0.11    |

Data presented as odds ratio with 95% confidence interval. Significant results are in italics. Abbreviations: DTT difficult-to-treat, PJI periprosthetic joint infection, LOS length of stay, ICU intensive care unit, OR odds ratio, CI confidence interval.
conclusions

In summary, the treatment of patients with PJI, especially DTT PJI, admitted to the ICU is complex and represents an ongoing challenge for surgeons and intensivists. The microbial spectrum of PJI in ICU-patients is in accordance with that reported in the literature. However, a high proportion of Ciprofloxacin-resistant Gram negative bacteria was noticed in ICU-patients with DTT PJI. ICU-patients with DTT PJI showed a higher proportion of polymicrobial PJI with higher numbers of pathogens, longer ICU stay and a higher mortality than patients with non-DTT PJI in univariate analysis. In multivariate analysis, prolonged ICU stay and DTT PJI were risk factors for hospital mortality so that the term of DTT pathogens may be useful for the intensivist to assess the clinical outcome in ICU-patients with PJI. Further studies need to investigate the role of DTT PJI in patients admitted to the ICU to emphasize the current findings.

Limitations

The current study has several limitations. First, it is a retrospective, observational, single-center study with missing data on follow-up after hospital discharge. Some patients may still develop an infection or may have a bad functional outcome. Second, detailed informations of the surgical and antibiotic treatment of PJI are not presented. Third, there are heterogenous definitions of PJI, DTT pathogens or of acute and chronic PJI and the available literature is lacking in comparable studies. Fourth, the number of patients with DTT PJI were small in our ICU cohort. Therefore, conclusion based on our results should be drawn carefully.

However, this study is the first to report the microbial findings of a large ICU cohort with special emphasis on DTT PJI treated in a tertiary healthcare center. The frequently number of patients with DTT PJI permit the analyses of risk factors for mortality.

References

1. Alp E, Cevahir F, Ersoy S, Guney A. Incidence and economic burden of prosthetic joint infections in a university hospital: A report from a middle-income country. J Infect Public Health 2016;9:494-8.
2. Portillo ME, Salvadó M, Alier A, et al. Prosthesis failure within 2 years of implantation is highly predictive of infection. Clin Orthop Relat Res 2013;471:3672-8.
3. Izakovicova P, Borens O, Trampuz A. Periprosthetic joint infection: current concepts and outlook. EFORT Open Rev 2019;4:482-94.
4. Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol Med Microbiol 2012;65:158-68.
5. Mirza YH, Tansey R, Sukeik M, et al. Biofilm and the Role of Antibiotics in the Treatment of Periprosthetic Hip and Knee Joint Infections. Open Orthop J 2016;10:636-45.
6. El Helou OC, Berbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010;29:961-7.
7. Gellert M, Hardt S, Köder K, et al. Biofilm-active antibiotic treatment improves the outcome of knee periprosthetic joint infection: Results from a 6-year prospective cohort study. Int J Antimicrob Agents 2020;55:105904.
8. Renz N, Trebse R, Akgün D, et al. Enterococcal periprosthetic joint infection: clinical and microbiological findings from an 8-year retrospective cohort study. BMC Infect Dis 2019;19:1083.
9. Akgün D, Perka C, Trampuz A, Renz N. Outcome of hip and knee periprosthetic joint infections caused by pathogens resistant to biofilm-active antibiotics: results from a prospective cohort study. Arch Orthop Trauma Surg 2018;138:635-42.
10. Faschingbauer M, Bieger R, Kappe T, et al. Difficult to treat: are there organism-dependent differences and overall risk factors in success rates for two-stage knee revision? Arch Orthop Trauma Surg 2020;140:1595-602.
11. Hipfl C, Winkler T, Janz V, et al. Management of critically infected total knee arthroplasty with severe bone loss using static spacers with intramedullary rods. J Arthroplasty 2019;34:1462-9.
12. Maaloum Y, Meybeck A, Olive D, et al. Clinical spectrum and outcome of critically ill patients suffering from prosthetic joint infections. Infection 2013;41:493-501.
13. Pöll AM, Backer H, Yilmaz et al. Risk factors and outcome of patients with periprosthetic joint infection admitted to intensive care unit. Arch Orthop Trauma Surg 2020;140:1081-5.
14. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
15. Keats AS. The ASA classification of physical status—Resuscitation. Anesthesiology 1978;49:233-6.
16. Charlson, ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
17. Ochsner PE. Infections of the musculoskeletal system - basic principles, prevention, diagnosis and treatment. 1st ed. Grandvaux: Swiss Orthopaedics; 2014.
18. Parvizi J, Tan TL, Gosswei K, et al. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. J Arthroplasty 2018;33:1309-14.
19. Li C, Renz N, Trampuz A. Management of Periprosthetic Joint Infection. Hip...
20. Triffault-Fillit C, Ferry T, Laurent F, et al. Microbiologic epidemiology depending on time to occurrence of prosthetic joint infection: a prospective cohort study. Clin Microbiol Infect 2019;25:353-8.
21. Zeller V, Kerroumi Y, Meyssonnier V, et al. Analysis of postoperative and hematogenous prosthetic joint-infection microbiological patterns in a large cohort. J Infect 2018;76:328-34.
22. Bjerke-Kroll BT, Christ AB, McLawhorn AS, et al. Periprosthetic joint infections treated with two-stage revision over 14 years: an evolving microbiology profile. J Arthroplasty 2014;29:877-82.
23. Lee YS, Fernando N, Koo KH, et al. What Markers Best Guide the Timing of Reimplantation in Two-stage Exchange Arthroplasty for PJI? A Systematic Review and Meta-analysis. Clin Orthop Relat Res 2018;476:1972-83.
24. Zmistowski B, Fedorka CJ, Sheehan E, et al. Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty 2011;26:104-8.
25. Kavolus JJ, Cunningham DJ, Rao SR, et al. Polymicrobial infections in hip arthroplasty: lower treatment success rate, increased surgery, and longer hospitalization. J Arthroplasty 2019;34:710-6.
26. Bozhkova S, Tikhilov R, Labutin D, et al. Failure of the first step of two-stage revision due to polymicrobial prosthetic joint infection of the hip. J Orthop Traumatol 2016;17:369-76.
27. Nana A, Neslon SB, McLaren A, et al. What’s new in musculoskeletal infection: update on biofilms. J Bone Joint Surg Am 2016;98:1226-34.
28. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645-54.
29. Kerckhoffs MC, Brinkmann S, de Keizer N, et al. The performance of acute versus antecedent patient characteristics for 1-year mortality prediction during intensive care unit admission: a national cohort study. Crit Care 2020;24:330.
30. Kisat MT, Latif A, Zogg CK, et al., Survival outcomes after prolonged intensive care unit length of stay among trauma patients: The evidence for never giving up. Surgery 2016; 160:771-80.